Aerosol inhalant containing interferon alpha and ipratropium bromide

A technology of aerosol inhalation and isopropyl deammonium bromide, which is applied in the directions of antiviral agents, respiratory diseases, active ingredients of heterocyclic compounds, etc. And other issues

Active Publication Date: 2012-04-18
BEIJING TRI PRIME GENE PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, there is no report on the combined use of interferon α and isopridine bromide for the treatment of viral pneumonia in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aerosol inhalant containing interferon alpha and ipratropium bromide
  • Aerosol inhalant containing interferon alpha and ipratropium bromide
  • Aerosol inhalant containing interferon alpha and ipratropium bromide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1: the preparation of the atomized inhalation of interferon α and isopropyl debromide

[0029] The nebulized inhalation of interferon α and isopridine bromide was prepared according to the method in Table 1 below. Among them, "Anfulong" (trade name) is the recombinant human interferon α2b injection with a specification of 50 μg / ml / bottle produced by Tianjin Hualida Bioengineering Co., Ltd.; "Interfern" (trade name) is Shenyang Sansheng Pharmaceutical Co., Ltd. Recombinant human interferon α2a injection with a specification of 50 μg / ml / bottle produced by the limited liability company; Interferon α1b injection, "Aiquanle" (trade name) is the iprodeammonium bromide solution for inhalation with a specification of 0.5mg / 2ml / bottle produced by Shanghai Boehringer Ingelheim Pharmaceutical Co., Ltd.; "PBS" is the solution containing 0.15mol / L NaCl in 25mmol / L disodium hydrogen phosphate-sodium dihydrogen phosphate buffer (pH7.0). Unless otherwise specified in the s...

Embodiment 2

[0033] Embodiment 2: the purity detection of isopropyl debromium after mixing interferon alpha and isopropyl debromium

[0034] The aerosolized inhalation of each interferon α and isopropyl debromide prepared by the method of Example 1 was carried out ultrafiltration treatment with Millipore ultrafiltration centrifuge tubes with a molecular weight cut-off of 3000Da after placing the preset time, and filtered Dilute the supernatant with deionized water to the same volume as before ultrafiltration and centrifugation, and then take 20 μl of KromasilC 8 Reversed-phase high-performance liquid chromatography column (5μm filler particle size, column size 4.6×150mm), chromatographic operation was performed at a column temperature of 35°C, the mobile phase was acetonitrile-0.25% sodium heptanesulfonate (29:71), and phosphoric acid was used Adjust the pH value to 3.2, the flow rate is 1.0ml / min, and the detection wavelength is 210nm. The measurement results are shown in Table 2 below. ...

Embodiment 3

[0038] Embodiment 3: Interferon alpha and isopropyl debromium content detection after mixing isopropyl debromium

[0039] The isopropyl debrominated ammonium reference substance (prepared by China Institute for the Control of Pharmaceutical and Biological Products, batch number 100522-200601) was dissolved and diluted with water respectively to a concentration of 0.0258, 0.0515, 0.1030, 0.2060, 0.3090 mg / ml and then according to the high-efficiency liquid phase of Example 2 Chromatographic conditions were applied to determine the peak area of ​​the main peak. Use the peak area (y) to perform linear regression on the concentration (x) to obtain a working curve, the equation is y=19000000x+11396, and the regression coefficient is r=0.9999.

[0040] The aerosolized inhalation of each interferon α and isopropyl debromide prepared by the method of Example 1 is carried out ultrafiltration centrifugation according to the method of Example 2 respectively after placing the preset time,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicinal compositions for resisting virus, and relates to an aerosol inhalant containing interferon alpha and ipratropium bromide. The aerosol inhalant contains a therapeutically effective amount of interferon alpha, a therapeutically effective amount of ipratropium bromide and an appropriate amount of pharmaceutic auxiliary materials; preferably, single dose of the aerosol inhalant contains 2.5 to 30mu g of interferon alpha, 0.025 to 0.2mg of ipratropium bromide and an appropriate amount of pharmaceutic auxiliary materials; and more preferably, single dose of the aerosol inhalant contains 10 to 20mu g of interferon alpha, 0.05 to 0.1mg of ipratropium bromide and an appropriate amount of pharmaceutic auxiliary materials. Compared with the interferon alpha or the ipratropium bromide, the aerosol inhalant containing the interferon alpha and the ipratropium bromide has the advantages that the effect of treating viral pneumonia can be improved obviously.

Description

technical field [0001] The invention relates to a composition of antiviral drugs and its application in the preparation of drugs for treating viral pneumonia. Background technique [0002] Viral pneumonia is a common disease in infants and young children, which seriously endangers the life and health of infants and young children. According to incomplete statistics, more than 90% of infants and young children have been infected with viral pneumonia before the age of 2, of which more than 80% of the cases are within 1 year old, the peak age of onset is 2-6 months, and severe cases can be seen in 1-6 months . The death rate of infants and young children caused by infection of viral pneumonia is 0.5%-2.0% in developed countries, up to 7% in developing countries, and it is the leading cause of infant death in my country. In addition, viral pneumonia is very contagious and reinfectious. It has been reported that family members can be infected successively, and the incidence of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/21A61K9/72A61P11/00A61P31/12A61K31/46
Inventor 周敏毅刘金毅徐晨宋文进李洁程永庆
Owner BEIJING TRI PRIME GENE PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap